A note on SARS-CoV-2 and cardiovascular disease

Author(s): Masataka Nishiga

This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http:// creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact reprints@pulsus.com OPINION A note on SARS-CoV-2 and cardiovascular disease Masataka Nishiga Citation: Nishiga M. A note on SARS-CoV-2 and cardiovascular disease. Clin Cardiol J 2022;6(1):1-1. OPINION he coronavirus disease 2019 (COVID-19) pandemic, which was caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, has resulted in millions of confirmed cases and deaths around the world. Rapid and large-scale testing is critical in patient management and slowing disease spread, hence efficient diagnostic instruments are in great demand. This study examines current SARS-CoV-2 detection technologies in clinical laboratories, as well as breakthroughs in molecular, antigenbased, and immunological point-of-care testing, as well asrecent sensor and biosensor device developments. The importance of specimen collection time and kind, as well as issues such as illness prevalence, setting, and procedures, are emphasised. The mechanisms of action of the various approaches, as well as their application breadth and known performance characteristics, are given in detail. The use of diagnostic imaging tools and biomarkers for measuring COVID-19 or monitoring disease severity or consequences is also covered. While the SARS-CoV-2 literature is continually expanding, this overview emphasises some of the most interesting events that occurred during the pandemic, as well as the lessons learned.

PDF